Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

A safety-modified SV40 Tag developed for human cancer immunotherapy

Authors Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al

Published Date January 2008 Volume 2008:2 Pages 17—24


Published 8 January 2008

Stephanie S Tseng-Rogenski1, Mohamed S Arredouani2, June F Escara-Wilke1, Yilin C Neeley1, Michael J Imperiale3, Martin G Sanda1,2

1Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, USA; 2Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 3Department of Microbiology and Immunology, School of Medicine, University of Michigan, Ann Arbor, MI, USA

Abstract: Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenecity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.
Keywords: modified SV-40 T antigen, recombinant vaccinia, cancer immunotherapy

Download Article [PDF] 

Readers of this article also read:

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab

Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T

OncoTargets and Therapy 2015, 8:243-249

Published Date: 27 January 2015

Mycobacterium marinum: a potential immunotherapy for Mycobacterium tuberculosis infection

Tian WW, Wang QQ, Liu WD, Shen JP, Wang HS

Drug Design, Development and Therapy 2013, 7:669-680

Published Date: 29 July 2013

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers

Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M

Drug Design, Development and Therapy 2012, 6:71-79

Published Date: 19 April 2012

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:117-124

Published Date: 10 March 2011

ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile

Aysegul Nalca, Elizabeth E Zumbrun

Drug Design, Development and Therapy 2010, 4:71-79

Published Date: 17 May 2010

Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model

Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al

Drug Design, Development and Therapy 2009, 3:17-26

Published Date: 17 December 2008

Beyond post-marketing research and MedWatch: Long-term studies of drug risks

David B Resnik

Drug Design, Development and Therapy 2007, 1:1-5

Published Date: 4 October 2007